The effects of cyclooxygenase (COX)-2 inhibition on ischemia-reperfusion injury in liver transplantation

Journal of Investigative Surgery

Volumn 22, Issue 4, 2009, Pages 239-245

  Oshima, Kiyohiro ^a   Yabata, Yoshihiro ^b   Yoshinari, Daisuke ^b   Takeyoshi, Izumi ^b  

^a GUNMA UNIVERSITY HOSPITAL   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase 2; Ischemia reperfusion injury; Liver transplantation

Indexed keywords

4' ACETYL 2' (2,4 DIFLUOROPHENOXY)METHANESULFONANILIDE; CYCLOOXYGENASE 2 INHIBITOR; THROMBOXANE B2; ANILIDE; CYCLOOXYGENASE 2; PRESERVATION SOLUTION;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DONOR; DRUG MECHANISM; DRUG MEGADOSE; INBRED STRAIN; LEWIS RAT; LIVER BLOOD FLOW; LIVER FUNCTION; LIVER GRAFT; LIVER ISCHEMIA; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SURVIVAL RATE; ANIMAL; METABOLISM; PATHOPHYSIOLOGY;

ANILIDES; ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; LIVER TRANSPLANTATION; MALE; ORGAN PRESERVATION SOLUTIONS; RATS; RATS, INBRED LEW; REPERFUSION INJURY;

EID: 73949092457     PISSN: 08941939     EISSN: 15210553     Source Type: Journal    
DOI: 10.1080/08941930903040080     Document Type: Article

References (29)

1. O'Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology 2008;134:1764-1776.
2. Koffron A, Stein JA. Liver transplantation: indications, pretransplant evaluation, surgery, and posttransplant complications. Med Clin N Am. 2008;92:861-888.
3. Duffy JP, Farmer DG, Busuttil RW. A quarter century of liver transplantation at UCLA. Clin Transpl. 2007;165-170.
4. Fondevila C, Busuttil RW, Kupiec-Weglinski JW. Hepatic ischemia/reperfusion injury: a fresh look. Exp Mol Pathol. 2003;74:86-93.
5. Howard TK, Klintmalm GB, Cofer JB, et al. The influence of preservation injury on rejection in the hepatic tranplant recipient. Transplantation 1990;49:103-107.
6. Casillas-Ramirez A, Mosbah IB, Ramalho F, et al.. Past and future approaches to ischemia-reperfusion lesion associated with liver transplantation. Life Sciences 2006;79:1881-1894. (Pubitemid 44488610)
7. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transplant. 2003;9:651-663.
8. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol. 1992;263(2 pt 2):F181-F191.
9. Mitchell JA, Larkin S, Williams TJ. Cyclooxygenase-2: regulation and relevance in inflammation. Biochem Pharmacol. 1995;50:1535-1542.
10. Oshima K, Takeyoshi I, Tsutsumi H, et al. Inhibition of cyclooxygenase-2 improves cardiac function following long-term preservation. J Surg Res. 2006;135:380-384.
11. Sunose Y, Takeyoshi I, Ohwada S, et al. The effect of cyclooxygenase-2 inhibitor FK3311 on ischemia-reperfusion injury in a canine total hepatic vascular exclusionmodel. J AmColl Surg. 2001;192:54-62.
12. Sunose Y, Takeyoshi I, Tsutsumi H, et al. Effects of FK3311 on pulmonary ischemia-reperfusion injury in a canine model. J Surg Res. 2001;95:167-173.
13. Nakamura K, Tsuji K, Konishi N, et al. Studies on antiinflammatory agents. III. Synthesis and pharmacological properties of metabolites of 4′ acetyl-2′ (2,4-difluorophenoxy) methanesulfonanilide (FK3311). Chem Pharm Bull. 1993;41:2050-2052. (Pubitemid 24015599)
14. Kamada N, Calne RY. Orthotopic liver transplantation in the rat: technique using cuff for portal vein anastomosis and biliary drainage. Transplantation 1979;28:47-50.
15. Littner MR, KazmiGM, Lott FD.Distribution of cyclooxygenase products with cyclooxygenase inhibition in isolated dog lung. J Appl Physiol. 1986;61:988-993.
16. Grossman CJ,Wiseman J, Lucas FS, et al. Inhibition of constrictive and inducible cyclooxygenase activity in human platelets andmononuclear cells by NSAIDs and Cox 2 inhibitors. Inflamm Res. 1995;44:253-257.
17. Naraba H, Murakami M, Matsumoto H, et al. Segregated coupling of phospholipases A2, cyclooxygenase and terminal prostanoid synthases in different phases of prostanoid biosynthesis in rat peritoneal macrophages. J Immunol. 1998;160:2974-2982.
18. Zamora CA, BaronDA, Heffner JE. Thromboxane contributes to pulmonary hypertension in ischemia-reperfusion lung injury. J Appl Physiol. 1993;74:224-229.
19. Tsuji K, Nakamura K, Konishi N, et al. Studies on antiinflammatory agents. IV. Synthesis and Pharmacological properties of 1,5-diarylpyrazoles and related derivatives. Chem Pharm Bull. 1997;45:987-995.
20. Tsuji K, Nakamura K, Konishi N, et al. Studies on antiinflammatory agents. I. Synthesis and pharmacological properties of 2′ phenoxy-methanesulfonanilide derivatives. Chem Pharm Bull. 1992;40:2399-2409.
21. Kawata K, Takeyoshi I, IwanamiK, et al. The effects of a selective cyclooxygenase-2 inhibitor on small bowel ischemia-reperfusion injury. Hepatogastroenterology 2003;50:1970-1974.
22. Ohtani Y, Takeyoshi I, Yoshinari D, et al. Effects of the COX-2 inhibitor FK3311 on ischemia-reperfusion injury in the rat lung. J Invest Surg. 2007;20:175-180.
23. Takeyoshi I, Sunose Y, Iwazaki S, et al. The effect of a selective cyclooxygenase-2 inhibitor in extended liver resection with ischemia in dogs. J Surg Res. 2001;100:25-31. (Pubitemid 32802699)
24. Simon LS. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med. 1999;106:37S-42S.
25. Harada N, Okajima K, Kushimoto S, et al. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic concentration of prostacyclin. Blood 1999;93:157-164.
26. Naka Y, Roy DK, Liao H, et al. cAMP-mediated vascular protection in an orthotopic rat lung transplant model. Insights into the mechanism of action of prostaglandin E1 to improve lung preservation. Circ Res. 1996;79:773-783.
27. Shinmura K, Tang XL, Wang Y, et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 2000;97:10197-10202.
28. Bolli R, Shinmura K, Tang XL, et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res. 2002;55:506-519.
29. Camitta MGW, Gabel SA, Chulada P, et al. Cyclooxygenase-1 and-2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation 2001;104:2453-2458.